Nutraceuticals as therapeutic agents for atherosclerosis

Area of Science:

• Nutritional Science
• Cardiovascular Medicine
• Pharmacology

Background:

• Atherosclerosis, a chronic inflammatory arterial disease, is a primary cause of cardiovascular disease (CVD), contributing to one-third of global deaths.
• Current CVD treatments, including statins, have limitations such as residual risk and patient side effects.
• Research for novel pharmaceutical CVD treatments has yielded disappointing results, with many candidates failing clinical trials.

Purpose of the Study:

• To review the potential of nutraceuticals as therapeutic agents for cardiovascular disease (CVD).
• To highlight specific nutraceuticals, including polyunsaturated fatty acids, flavonoids, and polyphenols, for their anti-CVD properties.
• To examine the clinical and pre-clinical evidence supporting nutraceuticals in CVD prevention and treatment.

Main Methods:

• Literature review of clinical and pre-clinical studies.
• Analysis of mechanism-based research on nutraceuticals' effects on atherosclerosis and CVD.
• Synthesis of data on polyunsaturated fatty acids, flavonoids, and polyphenols relevant to CVD.

Main Results:

• Nutraceuticals, derived from food sources, offer health benefits beyond nutrition.
• Specific compounds like polyunsaturated fatty acids, flavonoids, and polyphenols demonstrate potential anti-atherosclerotic and cardioprotective effects.
• Evidence suggests nutraceuticals can be effective in CVD prevention or as adjunctive therapy.

Conclusions:

• Nutraceuticals represent a promising avenue for managing cardiovascular disease (CVD).
• Further research into polyunsaturated fatty acids, flavonoids, and polyphenols could lead to novel therapeutic strategies.
• Nutraceuticals may offer a valuable approach to reduce residual risk and mitigate side effects associated with conventional CVD treatments.